Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 4:22 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 409–432 of 1,096 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Side Effects Clear all
Completed No phase listed Observational

Physical Functional Side Effects of Taxane Chemotherapy for Breast Cancer

NCT01153282
View directory record Official record
Conditions
Breast Cancer
Interventions
Not listed
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
21 Years to 70 Years · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 10, 2020 · Synced Oct 24, 2026, 4:22 AM EDT
Not yet recruiting Phase 1 Interventional

Impact of Using a GLP1 on Treatment Related Side Effects of Lung Cancer Patients Receiving Lorlatinib

NCT07782359
View directory record Official record
Conditions
Lung Cancer
Interventions
Tirzepatide
Drug
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 24, 2026, 4:22 AM EDT
Recruiting Phase 2 Interventional

Prospective Study on Radiation Induced Cardiotoxicity Assessed By PET-CT for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

NCT07761910
View directory record Official record
Conditions
Non Small Cell Lung Cancer, Cardiotoxicity, Locally Advanced Non-Small Cell Lung Cancer, Radiation Therapy
Interventions
PET/CT 18F-Flurpiridaz Rest/Stress Test, Coronary CT Angiography (CCTA), 18F-Flurpiridaz
Diagnostic Test · Device · Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 24, 2026, 4:22 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Assess Adverse Events and Change in Disease Activity of Risankizumab Subcutaneous Induction Treatment for Moderately to Severely Active Crohn's Disease.

NCT06063967
View directory record Official record
Conditions
Crohn's Disease
Interventions
Risankizumab SC, Placebo for risankizumab
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
289 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
79
States / cities
Sun City, Arizona • Corona, California • Coronado, California + 65 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Oct 24, 2026, 4:22 AM EDT
Completed No phase listed Observational

Microbiome, Antibiotics, and Growth Infant Cohort

NCT03001167
View directory record Official record
Conditions
Obesity, Childhood, Antibiotic Side Effect
Interventions
Not listed
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 96 Hours
Enrollment
509 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2023
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 12, 2024 · Synced Oct 24, 2026, 4:22 AM EDT
Completed No phase listed Observational

Cross-Sectional Iloperidone IVGTT

NCT01686815
View directory record Official record
Conditions
Schizophrenia, Serious Mental Illness, Metabolic Syndrome, Insulin Resistance, Glucose Metabolism
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 12, 2019 · Synced Oct 24, 2026, 4:22 AM EDT
Active, not recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate if Long Acting Cabotegravir (CAB) and Lenacapavir (LEN) Injections Are Tolerable and Acceptable When Administered to Healthy Adults Without HIV

NCT06970223
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir long-acting, Lenacapavir long-acting
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Nov 28, 2025 · Synced Oct 24, 2026, 4:22 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Corrections Work's Adverse Effects and a Total Worker Health Program to Enhance Well-being

NCT05608889
View directory record Official record
Conditions
Occupational Stress, Health Behavior, Safety Issues, Mental Health Wellness 1
Interventions
Total Worker Health Mindfulness Enhanced Program
Behavioral
Lead sponsor
Kerry Kuehl
Other
Eligibility
18 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Salem, Oregon • Wilsonville, Oregon
Source: ClinicalTrials.gov public record
Updated Feb 14, 2023 · Synced Oct 24, 2026, 4:22 AM EDT
Active, not recruiting Phase 1 Interventional

A Study to Assess Adverse Events, Tolerability, and Pharmacokinetics of Subcutaneous Injections of ABBV-295 in Healthy Adult Japanese Participants With Overweight or Obesity.

NCT07514260
View directory record Official record
Conditions
Healthy Volunteer
Interventions
ABBV-295, Placebo for ABBV-295
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Aug 14, 2026 · Synced Oct 24, 2026, 4:22 AM EDT
Completed Not applicable Interventional Results available

The Secure Messaging for Medication Reconciliation Tool (SMMRT) Trial

NCT02482025
View directory record Official record
Conditions
Drug-Related Side Effects and Adverse Reactions, Adverse Drug Events
Interventions
SMMRT
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 99 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 19, 2020 · Synced Oct 24, 2026, 4:22 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of the Safety, Pharmacokinetics and Efficacy of Tinostamustine in Patients With Advanced Solid Tumors.

NCT03345485
View directory record Official record
Conditions
Small Cell Lung Cancer, Soft Tissue Sarcoma, Triple-negative Breast Cancer, Ovarian Cancer, Endometrial Cancer
Interventions
Tinostamustine 60mg/m2 over 30min, Tinostamustine 80mg/m2 over 30min, Tinostamustine 100mg/m2 over 30min, Tinostamustine 60mg/m2 over 60min, Tinostamustine 80mg/m2 over 60min, Tinostamustine 100mg/m2 over 60min, Tinostamustine 80mg/m2 over 80min
Drug
Lead sponsor
Mundipharma Research Limited
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
5
States / cities
Los Angeles, California • Palo Alto, California • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2024 · Synced Oct 24, 2026, 4:22 AM EDT
Completed No phase listed Observational

Genetic Analysis in Identifying Late-Occurring Complications in Childhood Cancer Survivors

NCT00082745
View directory record Official record
Conditions
Childhood Malignant Neoplasm
Interventions
Laboratory Biomarker Analysis, Questionnaire Administration
Other
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 99 Years
Enrollment
3,885 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2026
U.S. locations
134
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Downey, California + 102 more
Source: ClinicalTrials.gov public record
Updated May 18, 2026 · Synced Oct 24, 2026, 4:22 AM EDT
Completed Not applicable Interventional Results available

Case Review of the Penumbra and Indigo Systems for Mechanical Thrombectomy in the Periphery

NCT02085551
View directory record Official record
Conditions
Peripheral Arterial Occlusion or Emboli
Interventions
Mechanical Thrombectomy by the Indigo System
Device
Lead sponsor
Penumbra Inc.
Industry
Eligibility
Not listed
Enrollment
85 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
5
States / cities
San Diego, California • Miami, Florida • Chicago, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2020 · Synced Oct 24, 2026, 4:22 AM EDT
Active, not recruiting Phase 3 Interventional

A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo

NCT06118411
View directory record Official record
Conditions
Vitiligo
Interventions
Upadacitinib, Placebo, NB-UVB (narrow-band ultraviolet B) Phototherapy
Drug · Other
Lead sponsor
AbbVie
Industry
Eligibility
12 Years and older
Enrollment
614 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
46
States / cities
Glendale, Arizona • Phoenix, Arizona • Encino, California + 35 more
Source: ClinicalTrials.gov public record
Updated Jun 9, 2026 · Synced Oct 24, 2026, 4:22 AM EDT
Active, not recruiting Phase 3 Interventional

Study to Assess Adverse Events, Change in Disease Activity, and How Oral Upadacitinib Moves Through the Body of Pediatric Participants With Moderately to Severely Active Ulcerative Colitis.

NCT05782907
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
Upadacitinib
Drug
Lead sponsor
AbbVie
Industry
Eligibility
2 Years to 17 Years
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2031
U.S. locations
20
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Corona, California + 16 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced Oct 24, 2026, 4:22 AM EDT
Completed Phase 3 Interventional

Study to Assess Change in Disease Activity and Adverse Events of Ab Externo Approach for Glaucoma Gel Stent (XEN45) Implantation In Participants Aged 45 Years or Older With Open-Angle Glaucoma

NCT05411198
View directory record Official record
Conditions
Open-Angle Glaucoma
Interventions
XEN45 (Glaucoma Gel Stent)
Device
Lead sponsor
AbbVie
Industry
Eligibility
45 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
23
States / cities
Fayetteville, Arkansas • Pasadena, California • Ventura, California + 19 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2026 · Synced Oct 24, 2026, 4:22 AM EDT
Suspended Not applicable Interventional

Patient-engaged Development and Testing of Educational Content on Side Effects of Statins

NCT07094412
View directory record Official record
Conditions
Dyslipidemia
Interventions
Educational content on statin side effects
Other
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2028 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 24, 2026, 4:22 AM EDT
Completed No phase listed Observational

Cost of Adverse Events Related to How Often Follow-Up Occurs Among Patients With Cancer That Has Spread

NCT03165409
View directory record Official record
Conditions
Melanoma
Interventions
Nivolumab, Ipilimumab
Biological
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
1,828 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
Princeton, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Oct 24, 2026, 4:22 AM EDT
Active, not recruiting Phase 2 Interventional

A Study Assessing Adverse Events and Disease Activity of Intravenously (IV) Infused Telisotuzumab Adizutecan in Adult Participants With c-Met Protein Above Cutoff Level Above Refractory Metastatic Colorectal Cancer

NCT06614192
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
Telisotuzumab Adizutecan
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
24
States / cities
Duarte, California • Irvine, California • Los Angeles, California + 20 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 24, 2026, 4:22 AM EDT
Recruiting Phase 3 Interventional

Penicillin Allergy Delabeling After a One-Dose Versus Two-Dose Graded Direct Oral Challenge

NCT06303128
View directory record Official record
Conditions
Penicillin Allergy
Interventions
Amoxicillin 250 MG, Placebo, Amoxicillin 62.5mg, Amoxicillin 187.5mg
Drug
Lead sponsor
James Tarbox, MD
Other
Eligibility
18 Years to 89 Years
Enrollment
380 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Oct 24, 2026, 4:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Effects of Blood Transfusion in Healthy Volunteers

NCT01226498
View directory record Official record
Conditions
Blood Transfusion, Autologous
Interventions
Red blood Cells auto-transfusion
Procedure
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 40 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 30, 2014 · Synced Oct 24, 2026, 4:22 AM EDT
Completed Not applicable Interventional Results available

Regional Data Exchange to Improve Medication Safety

NCT01239121
View directory record Official record
Conditions
Drug Toxicity
Interventions
HIE-Enhanced Medication Reconciliation, Optimal Medication Reconciliation without HIE
Other
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
402 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Aug 15, 2016 · Synced Oct 24, 2026, 4:22 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Cosmetic Effects of Topical Acetyl Zingerone

NCT03530787
View directory record Official record
Conditions
Wrinkle Appearance, Skin Pigment, Erythema, Side Effect, Microbiome, Lipidome
Interventions
Acetyl Zingerone Topical Cream, Topical cream
Other
Lead sponsor
University of California, Davis
Other
Eligibility
30 Years to 60 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 4, 2019 · Synced Oct 24, 2026, 4:22 AM EDT
Withdrawn Not applicable Interventional

Phenylephrine Dose and Mode of Administration for Spinal Anesthesia Induced Hypotension

NCT02101047
View directory record Official record
Conditions
Complications; Cesarean Section, Spinal Anesthetics Causing Adverse Effects in Therapeutic Use
Interventions
Phenylephrine
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 45 Years · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 24, 2026, 4:22 AM EDT